Trial Profile
A phase 1b/2a, multicenter, open-label study of AQ4N [banoxantrone] in combination with radiation therapy and temozolomide [Temodar] to evaluate the safety, tolerability, and efficacy in subjects with newly diagnosed glioblastoma multiforme
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Banoxantrone (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novacea; Transcept Pharmaceuticals Inc
- 06 Nov 2006 New trial record.